

Form PTO-1449

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

ATTY DOCKET NO.  
0020-4872P

APPLICATION NO.  
09/857,308

APPLICANT  
Kyogo, Itoh et al.

FILING DATE  
June 1, 2001

GROUP  
UNASSIGNED 1642

## U.S. PATENT DOCUMENTS

DOCUMENT NUMBER

DATE

NAME

CLASS

SUB CLASS

FILING DATE  
IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER

DATE

COUNTRY

CLASS

SUB CLASS

TRANSLATION  
YES NO

OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

CY

Gene Number (KIAA): 0764, Acc. No. ABO18307

CY

Nakao et al., "HLA A2601-restricted CTLs Recognize a Peptide Antigen Expressed on Squamous Cell Carcinoma"; Cancer Research; Vol. 55, pp.4248-4252; (1995)

CY

Kubo et al., "Definition of Specific Peptide Motifs for Four Major HLA-A Alleles"; J.of Immunology, Vol. 152, pp. 3913-3924 (1994)

CY

Kondo et al., "Prominent Roles of Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class I Molecules"; J.of Immunology, Vol.155, pp.4307-4312 (1995)

CY

Sudo et al., "Differences in MHC Class I Self Peptide Repertoires among HLA-A2 Subtypes"; The J. of Immunology, Vol.155, pp.4749-4756 (1995)

CY

Rivoltini et al., "Induction of Tumor-Reactive CTL from peripheral Blood and Tumor-infiltrating Lymphocytes of Melanoma Patients by In Vitro Stimulation with an Immunodominant Peptide of the Human Melanoma Antigen MART-1", The J. of Immunology, Vol. 154, pp.2257-2265 (1995)

CY

Kharkevitch et al., "Characterization of Autologous Tumor-Specific T-Helper 2 Cells in Tumor-Infiltrating Lymphocytes from a patient with Metastatic Melanoma", Int.J.Cancer, Vol. 58, pp. 317-323 (1994)

CY

Thomsen et al., "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination", The J. of Immunology, Vol.160, pp.1717-1723 (1998)

CY

Tsai et al., "Identification of Subdominant CTL Epitopes of the GP100 Melanoma-Associated Tumor Antigen by Primary in Vitro Immunization with Peptide-Pulsed Dendritic Cells", The J. of Immunology, Vol. 158, pp.1796-1802 (1997)

CY

Rosenberg et al., "Treatment of Patients with Metastatic Melanoma with Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2", J.Natl.Cancer Inst., Vol. 86, pp. 1159-1166 (1994)

CY

Altman et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes", Science, Vol. 274, pp. 94-96 (1996)

CY

Rammensee et al., "MHC ligands and peptide motifs: first listing", Immunogenetics, Vol. 41, pp. 178-228 (1995)

DATE CONSIDERED

7.23.03


EXAMINER

CHRISTOPHER YAEN

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JWB/bmp

0020-4872P



#12

Form PTO-1449  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  (Use several sheets if necessary)	ATTY DOCKET NO. 0020-4872P	APPLICATION NO. 09/857,308
	APPLICANT ITO et al.	
	FILING DATE June 1, 2002	GROUP 1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

RECEIVED

NOV 05 2002

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO

## OTHER DOCUMENTS

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

CY	RAMMENSEE et al., Immunogenetics, Vol. 41, pp. 178-228, (1995).

EXAMINER <b>CHRISTOPHER YARN</b>	DATE CONSIDERED <b>7.23.03</b>
-------------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.